It is sometimes difficult to distinguish gliomas from other tumors on routine imaging. In this study, we assessed whether 3-T magnetic resonance spectroscopy (MRS) with LCModel software might be useful for discriminating glioma from other brain tumors, such as primary central nervous system lymphomas (PCNSLs) and metastatic tumors. A total of 104 cases of brain tumor (66 gliomas, 20 PCNSLs, 6 metastatic tumors, 12 other tumors) were preoperatively investigated with short echo time (35 ms) single-voxel 3-T MRS. LCModel software was used to evaluate differences in the absolute concentrations of choline, N-acetylaspartate, N-acetylaspartylglutamate, glutamate + glutamine, myo-inositol (mIns), and lipid. mIns levels were significantly increased in high-grade glioma (HGG) compared with PCNSL (p < 0.001). In multivariate logistic regression analysis, mIns was the best marker for differentiating HGG from PCNSL (p < 0.0001, odds ratio 1.9927, 95% confidence interval 1.3628-3.2637). Conventional MRS detection of mIns resulted in a high diagnostic accuracy (sensitivity, 64%; specificity, 90%; area under the receiver operator curve, 0.80) for HGG. The expression of inositol 3-phosphate synthase (ISYNA1) was significantly higher in gliomas than in PCNSLs (p < 0.05), suggesting that the increased level of mIns in glioma is due to high expression of ISYNA1, the rate-limiting enzyme in the mIns-producing pathway. In conclusion, noninvasive analysis of mIns using single-voxel MRS may be useful in distinguishing gliomas from other brain tumors, particularly PCNSLs.
Introduction
Glioma, especially high-grade glioma (HGG), is one of the most common primary brain tumors, accounting for 25-30% of all intracranial tumors, in adults and has one of the worst outcomes [1] . It is usually diagnosed via histological examination because there are neither diagnostic biomarkers in the cerebrospinal fluid and serum, or specific imaging findings. A typical feature of HGG on magnetic resonance imaging (MRI) is a ring-like enhancing ill-demarcated mass lesion with peritumoral edema. However, this feature is quite similar to that of other brain tumors, such as metastatic tumors and primary central nervous system lymphomas (PCNSLs).
The standard treatment for glioma is maximal safe gross surgical resection, followed by radiotherapy and/or chemotherapy [2] . Stereotactic biopsy is usually performed for PCNSLs to obtain the histological diagnosis because PCNSLs are highly sensitive to chemotherapy and radiotherapy and the impact of the extent of resection on survival is low [3] . Total resection with craniotomy is occasionally performed for metastatic brain tumors. However, preoperative diagnosis of metastatic brain tumors is frequently made via imaging findings of multiple tumors in the brain and a primary tumor in another organ, in combination with tumor markers such as CEA and CA19-9 in the serum and/or cerebrospinal fluid [4, 5] . PCNSL is uncommon, representing approximately 3-5% of primary brain tumors, although its incidence has increased recently [6] . Because gliomas and PCNSLs have similar imaging findings ( Fig. 1a) but require different surgical approaches, the development of a noninvasive preoperative detection method for these tumors is of clinical interest.
Arterial spin labeling and the apparent diffusion coefficient, which evaluate tumor vascularity and cellularity, are useful for the differentiation of these tumors [7] [8] [9] [10] . Intravoxel incoherent motion (IVIM) and (F-18)2-deoxy-2-fluoro-d-glucose (FDG-PET) also play important roles in differentiating glioblastoma and PCNSL [11] . Although amide proton transfer-weighted imaging (APTW) [12] , can differentiate these two tumors, these methods are not readily available on mainstream clinical scanners.
Magnetic resonance spectroscopy (MRS) is unique in that it can noninvasively predict tumor type by evaluating metabolic information (Fig. 1b) . Recent several studies reported the utility of conventional MRS in differential diagnosis. These reports indicated that the lipid/creatine ratio, glutamate/creatine ratio, glutamate/glutamate + glutamine ratio, and choline/creatine ratio on short echo time (TE) MRS may be useful in differentiating glioblastoma and PCNSL [13, 14] . However, lipids are affected by necrosis and glutamate is decreased by the isocitrate dehydrogenase (IDH) 1 mutation in some gliomas. In addition, these reports did not evaluate the diagnostic performance of MRS. These findings motivated us to evaluate other metabolites that could more precisely distinguish gliomas from other brain tumors, especially PCNSLs, and to determine whether MRS could help in glioma diagnosis.
Methods

Study design and study population
Subjects were 115 patients with an intracranial tumor or a suspected intracranial brain tumor who were treated at the Department of Neurosurgery, Kobe University Hospital, between August 2013 and August 2016. This study was approved by the ethics review boards of our institutions (approval numbers: #1497 for MRS; #1579 for use of tumor samples). Informed consent was obtained from all patients prior to their inclusion in this study.
All patients underwent preoperative MRI and MRS within 1 week prior to surgery. Samples were resected during surgery at the exact targets indicated by MRS using an intraoperative navigation system (Brain LAB™) and immediately frozen in liquid nitrogen for subsequent investigation. Histopathological classification and tissue grading were performed by a board-certified neuropathologist. The IDH gene status of all glioma cases was analyzed by immunohistochemistry for IDH R132H and DNA sequencing of IDH1 and IDH2. The IDH gene status of all PSNSL cases was analyzed by immunohistochemistry.
Of the 115 patients enrolled, 77 with glioma, 20 with PCNSL, 6 with metastatic tumor, and 12 with other tumors had MRS data as assessed by the objective criteria defined below in the section "MRI and MRS". However, 11 were excluded before analysis of the correlation between MRS results: three had a signal-to-noise ratio (SNR) < 5 (anaplastic astrocytoma, n = 1; glioblastoma, n = 2), one had a full width at half maximum (FWHM) of more than 0.065 ppm (oligodendroglioma, n = 1), and seven had a necrotic lesion with an insufficient volume of solid component (glioblastoma, n = 7). Thus, we ultimately analyzed 104 intra-axial brain tumor patients with glioma (grade I, n = 4; grade II, n = 17; grade III, n = 15; grade IV, n = 30), PCNSL (diffuse large B cell lymphoma, n = 20), metastatic tumor (lung cancer, n = 3; rectal cancer, n = 2, stomach cancer, n = 1), and other tumors (central neurocytoma, n = 3; meningioma, n = 3; germ cell tumor, n = 3; gliosis, n = 3). As a control, voxels were also placed in the same anatomical location on the contralateral (non-tumor) side of the brain (glioma, n = 60; PCNSL, n = 20). Of the 66 glioma patients, 3 had pilocytic astrocytoma, 1 had subependymal giant cell astrocytoma, 10 had diffuse astrocytoma, 9 had anaplastic astrocytoma, 30 had glioblastoma,
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6 had oligodendroglioma, 6 had anaplastic oligodendroglioma, and 1 had oligoastrocytoma.
All of the PCNSL patients were diagnosed with diffuse large B cell lymphoma. Mean patient age was significantly lower for those with gliomas (age range, 17- 
MRI and MRS
The MRS signal was acquired using a 3.0-T MRI/1H-MRS scanner (Achieva; Philips Medical Systems, Best, The Netherlands) [15] . An 8-channel head MRI coil was used for signal reception and a quadrature body MRI coil was used for transmission of the radiofrequency pulses. Following routine preoperative MR imaging, FLAIR and T2* images were taken to localize the corresponding target. Single-voxel localized MR spectra were acquired using a double-echo point-resolved spectroscopic ; repetition time/TE = 2000/35 ms; number of acquisitions, 128 averages; and 1024 complex points for the spectral data. Volumes of interest were localized to representative areas of the solid tumor, which were assessed by a board-certified radiologist (RS) or technician (KK). Regions of necrosis, hemorrhage, or peripheral edema were excluded from the corresponding region. The unsuppressed water signal was obtained using the abovementioned parameters.
The FWHM and SNR of the MR spectra were assessed. Spectra with an FWHM of N-acetylaspartate (NAA) > 0.065 ppm or a SNR < 5 were excluded using these objective criteria [16] . MRS data were quantified with LCModel version 6.3 (Stephen Provencher, Oakville, Ontario, Canada) using a basis set, which was developed using MR experiment simulation software (GAMMA, Radiology, Duke University Medical Center, Durham, NC) and calibrated with an MRS phantom. The basis set contained 19 metabolites (Supplementary Table 1 ). The water-suppressed spectral data were examined between 0.6 and 4.0 ppm. The absolute metabolite concentrations (mM) were estimated using the unsuppressed water signal as a reference. Water concentration in the voxel was 35.88M as default. Absolute concentrations of choline (Cho), N-acetylaspartate (NAA) + N-acetylaspartylglutamate (NAAG), glutamate + glutamine (Glx), creatine (Cr), myo-inositol (mIns), lipid13a + 13b + 09 + 20 (Lip), lactate (Lac), and other metabolites are reported in mM.
Metabolites were quantified with Cramer-Rao lower bounds (CRLBs). The CRLB values were calculated from the residual error and the Fisher matrix of the partial derivatives of the concentrations [17] . These CRLB values reflect the variance of the spectra fitting estimate but not its accuracy, and they indicate how close repeated measurements will be to the current measurement under similar experimental conditions. All metabolites were excluded when the CRLB was > 30%.
Histological diagnosis and IDH gene status of clinical specimens
Surgical specimens were analyzed by a board-certified neuropathologist at Kobe University Hospital. Histological diagnosis and grading of the tissue were performed according to the 2007 WHO guidelines. IDH1 R132H analysis was confirmed via immunohistochemistry and DNA sequencing [18] . Detailed protocols are found in the Supplementary Materials and Methods.
Real-time PCR analysis
We also conducted integrated analyses of clinical samples (48 glioma and 39 PCNSL tumor samples) to examine expressions of various metabolic enzymes in the gliomas and PCNSLs. RNA extraction and real-time PCR analysis were performed as previously described [19] . Quantitative real-time PCR using TaqMan ® Gene Expression Assays was performed using an Applied Biosystems 7500 real-time PCR system. The 18S ribosomal RNA was used as the endogenous control. All reactions were performed in triplicate. The quantitative mRNA expression data were analyzed using the ΔΔCt method. The following TaqMan ® Gene Expression Assays were used: ISYNA1 (SMID: Hs01126940_ gH), IMPA1 (SMID: Hs04188597_m1), SLC5A3 (SMID: Hs00272857_s1), and 18S (SMID: Hs99999901_s1).
Statistical analysis
The Mann-Whitney U test between two groups and SteelDwass test between more than three groups were used to examine statistical differences because to the data differences were not normally distributed. Statistical significance was considered significant at p < 0.05. A multivariate logistic regression model analysis was used to determine the best predictor of the differential diagnosis of glioma and PCNSL. To assess diagnostic accuracy, receiver operating characteristic (ROC) curve analysis was used. Area under the ROC curve (AUC) values for discrimination were calculated. All statistical analysis was performed using the JMP 11 package (SAS Institute Japan, Tokyo, Japan).
Results
Metabolite concentrations among tumors
Because metabolites were excluded when the CRLB was > 30%, we analyzed five metabolites, Cho, NAA + NAAG, Glx, mIns, and Lip. First, we compared the concentrations of these metabolites among gliomas and other tumors (metastatic tumors, PCNSLs, and others). Lip levels were significantly lower in gliomas than in the other tumors, while mIns levels were significantly higher in gliomas than in the other tumors (Mann-Whitney nonparametric U test, p < 0.01, p < 0.001, respectively; Fig. 2) . Cho, NAA + NAAG, and Glx were not significantly different between the two groups. mIns levels were significantly higher in gliomas than in metastatic tumors or PCNSLs, but there were no differences between gliomas and the contralateral normal brain (Steel-Dwass test, p < 0.01, p < 0.001, respectively; Supplementary Fig. 1B ). In addition, Lip levels were significantly lower in gliomas than in metastatic tumors or PCNSLs (Supplementary Fig. 1A ). However, there were no significant differences between metastatic tumors and PCNSLs ( Supplementary Fig. 1A ). These results suggest that mIns, and Lip could be differential metabolites between glioma and other tumors.
Metabolite concentrations based on glioma grade
Next, to determine whether metabolites are affected by the glioma tumor grade, we compared the concentrations of the 6 metabolites among grades I, II, III, and IV. Glx and Lip concentrations showed a clear trend for an increase from grades II to IV (Steel-Dwass test, grade II vs IV, p < 0.001; Fig. 3a) . Cho, NAA + NAAG, and mIns concentrations were not significantly different among tumor grades. However, the mIns concentration in grade IV glioma (glioblastoma) tended to be decreased compared with other grades. The mIns/Cr ratio was not significantly different among glioma grades (Fig. 3b) .
Due to the metabolic change caused by the IDH mutation, we investigated the levels of metabolites in gliomas according to the presence of IDH wild-type and IDH mutant. Twenty-three gliomas had IDH1 mutantation and 39 had wild-type IDH1. The Glx concentration was significantly lower in IDH mutant glioma than in IDH wild-type glioma (Mann-Whitney U test, p < 0.001; Supplementary Fig. 2 ). There were no significant differences in the concentrations of mIns, Lip, Cho, and NAA + NAAG between IDH mutant glioma and IDH wild-type glioma ( Supplementary Fig. 2 and data not shown). The 2-hydroxyglutarate (2HG) concentration was significantly higher in IDH mutant glioma (median 1.429 mM, range 0-14.117) than in IDH wild-type glioma (median 0 mM, range 0-2.84) (Mann-Whitney U test, p < 0.001). The CRLB of 2HG in IDH mutant type glioma (median 71, range 11-999) was significantly lower than in IDH wild-type glioma (median 999, range 40-999) (Mann-Whitney U test, p < 0.001).
Myo-inositol is a useful differential metabolite between glioma and PCNSL
Because the MRI features are quite similar between HGG and PCNSL and because it is difficult to diagnose HGG and PCNSL, we investigated the metabolic changes in HGG and PCNSL. Lip levels were significantly higher in PCNSLs than in HGGs (Mann-Whitney U test, p < 0.001, respectively; Fig. 4a ). mIns levels were significantly lower in PCNSLs than in HGGs (Mann-Whitney U test, p < 0.001, respectively; Fig. 4a ). There was no difference in mIns levels between metastatic brain tumor and PCNSLs (Supplementary Fig. 3) . However, the mIns concentration was higher in HGG than in PCNSL and the mIns/Cr ratio was not significantly different between HGG and PCNSL. HGG had a slightly higher concentration of Cr (p < 0.05; Supplementary  Fig. 4 ). In multivariate logistic regression analysis, mIns (p < 0.0001; odds ratio [OR] 1.9927, 95% confidence interval [CI] 1.3628-3.2637) were significant variables that could be used to independently differentiate HGG from PCNSL (Table 1) .
Next, we investigated the discriminatory power of mIns in HGG and other tumors using the ROC curve method. ROC curve analysis gave the following results: mIns concentration > 3.63 mM was 64% sensitive and 90% specific for differentiating HGG from PCNSL (AUC 0.80; Fig. 4b ). These results indicate that mIns may be the most useful metabolite for differentiating HGG from PCNSL in MRS.
Because there are three metabolic enzymes in the mInsproducing pathway-ISYNA1 (inositol 3-phosphate synthase), IMPA1/2 (myo-inositol 3-phosphate monophosphatase), and SLC5A3 (solute carrier family 5/inositol transporter, member 3; Supplementary Fig. 5A )-we examined the mRNA expressions of these enzymes in the tumor tissues of gliomas and PCNSLs. The expression of ISYNA1, the rate-limiting enzyme that catalyzes the first step in the biosynthesis of mIns, was significantly higher in gliomas than in PCNSLs (p < 0.001; Fig. 4c ), although there were 
Discussion
This study shows that mIns and Lip are useful diagnostic metabolites in gliomas. Furthermore, mIns is useful differential metabolites between HGG and PCNSLs. In particular, the levels of mIns were significantly higher in gliomas than in PCNSLs. Conventional MRS detection of mIns had a high diagnostic accuracy (AUC 0.80) for HGG. mIns is one of the most abundant metabolites in the brain, with a peak at 3.56 ppm on short TE MRS. It is a sugar-like molecule that acts as an osmolyte and is involved in various key biochemical processes, such as signal transduction [20] , phosphorylation of target proteins [21] , chromatin remodeling and gene expression [22] , and mRNA transport [23] . The brain manifests very high levels of mIns, particularly in astrocytes [24, 25] . The mIns concentration is increased in various brain disorders including reactive astrogliosis and brain tumors (ependymomas and choroid plexus papillomas). In the present study, the mIns concentration was not significantly different among glioma grades, in line with a previous report [26] . Some authors have shown that the mIns/Cr ratio is higher in low-grade astrocytoma than in HGG [25] , but the mIns/Cr ratio in our study was not significantly different among glioma grades.
A previous study found that mIns was useful for discriminating PCNSL and astrocytomas on 1.5-T short TE MRS [12] . However, to the best of our knowledge, ours is the first study to show the diagnostic accuracy of mIns in discriminating HGG and PCNSL using 3-T MRS with LCModel software. In addition, we found no difference in the mIns/ Cr ratio between HGG and PCNSL, in line with previous studies [13, 14] , because the Cr concentration was higher in HGG than in PCNSL [13] . Cr is widely known to be a marker of cellular energy and correlates with cell density and Cr has been used as an internal control. However, to distinguish HGG from PCNSL, concentration of the mIns seems to be more useful than mIns/Cr ratio.
We also analyzed the mRNA expression of metabolic enzymes related to mIns in tumor tissues. The expression level of ISYNA1 was found to be significantly increased in gliomas compared with PCNSLs. ISYNA1 is a rate-limiting enzyme that catalyzes the first step in the biosynthesis of mIns. It converts glucose-6-phosphate to inositol-1-phosphate, which is then dephosphorylated by IMPA1 to synthesize mIns [27] . Several studies have suggested the hormonal regulation of ISYNA1 expression, but very little is known about the regulation of ISYNA1. Seelan et al. [28] reported that E2F1, a transcription factor promoting the cell cycle, could upregulate ISYNA1 expression. Notably, Wei et al. [29] showed that a high concentration of mIns in tumors is associated with high levels of ISYNA1. In addition, because ISYNA1 is the rate-limiting enzyme in myo-inositol biosynthesis, myo-inositol biosynthesis is equivalent to myoinositol 1-phosphate biosynthesis [30] . In the present study, the mRNA levels of ISYNA1 were significantly elevated in glioma tissue compared with PCNSLs. These findings suggest that the expression levels of ISYNA1 may affect the mIns concentration in brain tumors.
Lip, with a peak at 1.2 ppm, is a useful biomarker to discriminate between PCNSL and glioblastoma on short TE MRS [14, 31] . A recent study showed that total Lip levels tend to be higher in HGG than in low grade glioma [32] . Therefore, a selection bias may have led to a low Lip concentration in the HGG group in this study. In addition, Lip seemed to be related to tumor necrosis, which is considered an indicator of malignancy and poor prognosis [32, 33] . Therefore, evaluation of Lip alone may be insufficient to discriminate HGG and PCNSL.
In present study, MRS detection of mIns provided sensitivity of 64%, specificity of 90%, and area under the receiver operator curve of 0.80 for HGG. These result seems to high specificity but sensitivity is average compared with previous literature in similar patient populations. Several studies have examined the diagnostic performance for distinguishing high grade glioma from PCNSL. The sensitivity and specificity of the rCBF in perfusion MRI for discriminating between PCNSLs and glioblastomas are 97 and 80% [8] . The ADCs of gliomas were higher than those of PCNSLs (sensitivity and specificity 80-90%) [9] . The diagnostic accuracy of IVIM MR between glioblastomas and PCNSLs were sensitivity 79.3%, specificity 69.2%, and AUC 0.756 and diagnostic accuracy could be increased to AUC 0.936 by also considering FDG-PET [11] . In addition, ABPW had a high diagnostic accuracy (sensitivity 100%, specificity 84.6%, AUC 0.963) [12] . Because there is no complete single imaging biomarker, MRS combined with other imaging modalities should be used.
There are some limitations to this study. First, the study was retrospective and the sample size was small. In particular, there were few metastatic and other tumors. A prospective large-scale validation study is thus needed. Second, we excluded 11 glioma patients due to a low SNR, high FWHM, or necrosis, which might represent a selection bias. Third, the mIns peak overlaps with the glycine peak and unambiguous assignment of the glycine signal may not be possible, especially at a short TE. Indeed, a high glycine level has been found in glioblastomas [34] . Because glycine is detectable at a long TE, we have to use additional long TE manual data to distinguish the glycine peak from mIns. Otherwise, ex vivo analysis of the concentrations of mIns and glycine in tumor tissues using mass spectrometry is needed. Fourth, metabolite concentration by LCModel without correction of T1 and T2 relaxation may differ from absolute concentration by typically 20% or more. However, if we do not change relaxation times and acquisition parameters during a study, we may evaluate reasonably consistent measures of absolute concentrations e.g., increases or decreases of metabolites. Finally, although the precision of the cutoff values for maximal diagnostic accuracy were set in this study, some mIns value overlaps in HGG and PCNSL. LCModel fitting results in high CRLB due to un-optimized MRS protocol for Glx and 2HG detection. Spectral overlap may cause contamination between quantification of these metabolites. Therefore the accuracy of ROC analysis and the conclusions of this study may be negatively impacted, and may be improved with an optimized protocol.
In conclusion, mIns levels may be a useful diagnostic marker for gliomas. MRS evaluation of mIns could provide quantitative information for differentiating HGG from PCNSL. MRS may be useful as an adjunct to another modality for the diagnosis of HGG and PCNSL.
